BRCA1 and familial pancreatic carcinoma: This is the first study to demonstrate synergistic interactions between PARPis (olaparib or talazoparib) and panobinostat, vorinostat, and decitabine in pancreatic cancer cell lines with wild-type BRCA1/2 (BxPC-3 or PL45) or BRCA2 mutation (Capan-1).